Buy Retatrutide Online — Triple Agonist from Ultima Pharmaceuticals

Also known as: LY3437943 · Triple agonist · GIP/GLP-1/Glucagon agonist · Eli Lilly triple G

Retatrutide is a next-generation triple incretin receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously — the most comprehensive hormonal weight loss mechanism available in any single compound. Phase 2 clinical trial data shows average weight loss of up to 24% of total body weight, surpassing both Semaglutide and Tirzepatide. Currently in Phase 3 trials, Retatrutide represents the cutting edge of pharmacological weight management. All products at U Store are sourced from verified manufacturers, independently lab-tested, and shipped discreetly worldwide.

We found 3 products available for you.

$225.00

Pharmaqo – Retatrutide 10mg

Retatrutide

1 vial x 10 ml x 10 mg

Clients Review:

07.01.2026

JohnyD

only been on it 3 weeks so can't give a full review yet but early signs are very promising. stronger appetite suppression than tirz which was already strong for me. slight nausea on injection day but gone by day 2. will update after 8 weeks. $225 is expensive but if the results hold up it's worth it

$112.00

Ultima-Retatrutide 10mg

Retatrutide

1 vial x 10 ml x 10 mg

Out Of Stock

$186.00

RETATRUSIN 10mg - A-TECH LABS

Retatrutide

1 vial x 10 ml x 10 mg

Out Of Stock

Clients Review:

07.01.2026

TripleAgonist

This is next level. Came from tirzepatide thinking it couldn't be that much better. It is. Week 3 at 4mg and appetite is basically nonexistent. Down 11lbs in 5 weeks without even trying to eat clean. Energy is actually up which I didn't expect. The glucagon component must be doing something to metabolism because I'm eating less and somehow feeling better. Reconstitution was easy, vial quality looks good. At $186 for 10mg this is genuinely worth every dollar if fat loss is the goal.

About Retatrutide

Retatrutide is a synthetic peptide developed by Eli Lilly that acts as a balanced agonist at three distinct receptor types — GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and the glucagon receptor. The addition of glucagon receptor agonism to the dual incretin mechanism of Tirzepatide is the key pharmacological advancement that distinguishes Retatrutide and appears to be responsible for its superior weight loss outcomes in clinical data.

Mechanism of action

GIP and GLP-1 receptor activation drive appetite suppression, improved insulin secretion, and slower gastric emptying — the same mechanisms shared with Semaglutide and Tirzepatide. The glucagon receptor component adds a third and distinct mechanism: glucagon is a catabolic hormone that stimulates hepatic glucose production and — critically for weight loss — increases energy expenditure and fat oxidation. By co-activating glucagon receptors alongside the two incretin pathways, Retatrutide simultaneously reduces caloric intake through appetite suppression and increases caloric output through enhanced metabolic rate. This dual-sided energy balance intervention explains the superior weight loss data compared to single or dual agonists.

Clinical trial data

Phase 2 trial results published in 2023 showed that Retatrutide at 12mg weekly produced average weight loss of approximately 24% of total body weight over 48 weeks in non-diabetic obese participants — with the highest dose group showing a mean reduction approaching 25% and a significant proportion losing more than 30% of body weight. These are the most impressive weight loss outcomes ever recorded for a pharmacological agent in clinical trials, prompting significant interest from both the medical community and performance sports users.

Use in performance sports

Among performance and bodybuilding users Retatrutide has gained significant attention for extreme cutting phases where maximum fat loss in minimum time is the objective. Its triple mechanism provides stronger appetite suppression than either Semaglutide or Tirzepatide while simultaneously elevating metabolic rate through the glucagon component — making it the most potent tool currently available for accelerated fat loss. Users typically combine it with high protein intake, structured resistance training, and potentially anabolic compounds to protect lean mass during what can be very aggressive caloric deficits.

Current status and availability

Retatrutide is currently in Phase 3 clinical trials and does not yet have regulatory approval in any market. It is available through research and gray market channels. Given its relatively recent emergence compared to Semaglutide and Tirzepatide, long-term safety data is more limited, and users should approach it with appropriate consideration of the current evidence base.

Frequently Asked Questions

What is Retatrutide and how does it work?

Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist developed by Eli Lilly. It builds on the dual incretin mechanism of Tirzepatide by adding glucagon receptor activation, which increases energy expenditure and fat oxidation on top of the appetite suppression and insulin-sensitizing effects of GIP and GLP-1 agonism. This triple mechanism produces greater weight loss than any currently approved pharmacological agent.

How does Retatrutide compare to Semaglutide and Tirzepatide?

Clinical data places average weight loss outcomes in the following order: Semaglutide approximately 15 to 17%, Tirzepatide approximately 20 to 22%, Retatrutide approximately 24% or greater at maximum doses. The key distinction is that Retatrutide does not just reduce caloric intake — it also increases energy expenditure through glucagon receptor activation, addressing both sides of the energy balance equation.

What dose of Retatrutide is used?

In Phase 2 trials, doses ranged from 1mg to 12mg administered weekly by subcutaneous injection. The dose showing the best efficacy to tolerability ratio was 8mg to 12mg weekly. As with other GLP-1 class compounds, titration from a low starting dose is essential to minimize gastrointestinal side effects.

What are the side effects of Retatrutide?

The side effect profile is similar to other incretin-based compounds — predominantly gastrointestinal symptoms including nausea, vomiting, diarrhea, and reduced appetite, most pronounced during dose escalation. The glucagon receptor component may produce slightly more pronounced effects on heart rate and metabolic parameters compared to GLP-1 only compounds. Long-term safety data is more limited given the compound's relatively recent emergence.

Is Retatrutide approved?

As of 2025, Retatrutide is in Phase 3 clinical trials and does not have regulatory approval in any major market. It is the most advanced compound of its class without approval, with Eli Lilly targeting a regulatory submission following completion of the Phase 3 program.

Does Retatrutide cause muscle loss?

The significant caloric deficit induced by Retatrutide's powerful appetite suppression creates a real risk of lean mass loss if diet and training are not managed appropriately. The glucagon component also has mild catabolic properties. Performance users typically ensure very high protein intake, consistent resistance training, and may use anabolic compounds concurrently to protect lean tissue during use.